Key Takeaways
Mirati Therapeutics, now a key part of Bristol Myers Squibb's oncology portfolio following a $4.8 billion acquisition completed in January 2024, developed Krazati (adagrasib) as a targeted therapy for non-small cell lung cancer (NSCLC). This oral small-molecule inhibitor specifically targets the KRAS G12C mutation, a challenging driver mutation found in approximately 14% of NSCLC adenocarcinomas. Krazati received accelerated FDA approval on December 12, 2022, for adult patients with locally advanced or metastatic KRAS G12C-mutated NSCLC who have received at least one prior systemic therapy.
This accelerated approval was based on data from the KRYSTAL-1 study, which showed an objective response rate (ORR) of 43% and a median duration of response (DOR) of 8.5 months in previously treated patients. The drug's ability to penetrate the central nervous system (CNS) is a notable differentiator, offering potential benefits for patients with brain metastases, a common and severe complication in NSCLC. This feature positions Krazati as a valuable option in a difficult-to-treat patient population.
However, Krazati's journey hasn't been without hurdles. In July 2023, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Conditional Marketing Authorisation Application for adagrasib in the EU. Mirati, now BMS, disagreed with this assessment, citing Krazati's differentiated clinical profile, including its CNS activity and combinability, and has requested a formal re-examination. This regulatory setback in Europe underscores the competitive and stringent landscape for novel oncology therapies, even those with promising early data.
The FDA's accelerated approval pathway, while offering quicker access to patients with unmet needs, mandates confirmatory trials to verify clinical benefit. For Krazati, this means the ongoing KRYSTAL-12 study is paramount. Its outcome will not only determine full FDA approval but also significantly influence Krazati's commercial trajectory and its standing against rival therapies in the burgeoning KRAS inhibitor market.
The immediate future for Krazati hinges significantly on the results of the KRYSTAL-12 study, a Phase 3 confirmatory trial evaluating adagrasib against docetaxel in patients with previously treated locally advanced or metastatic NSCLC harboring a KRAS G12C mutation. This trial is designed to provide the robust efficacy and safety data required for full FDA approval, moving beyond the initial accelerated pathway. Importantly, KRYSTAL-12 includes patients who have already received platinum-based chemotherapy and anti-PD-(L)1 therapy, mirroring the real-world second-line treatment setting.
Mirati has indicated that progression-free survival (PFS) and interim overall survival (OS) results from KRYSTAL-12 are anticipated in the first half of 2024. A positive outcome, demonstrating a statistically significant improvement in PFS over docetaxel, would solidify Krazati's position and potentially broaden its market penetration. The trial's design allows for crossover from docetaxel to Krazati upon confirmed disease progression, which is a common feature in oncology trials aiming to provide patients with access to effective therapies.
This confirmatory data is not just about regulatory checkboxes; it's about market differentiation. While Amgen's Lumakras (sotorasib) was the first KRAS G12C inhibitor approved, Krazati's KRYSTAL-1 data showed a higher ORR (43% vs. Lumakras's 28% in similar populations) and confirmed CNS activity. Strong KRYSTAL-12 results could reinforce Krazati's clinical edge, particularly if it demonstrates superior PFS or OS, or a more favorable safety profile compared to docetaxel, which is a standard chemotherapy option.
Beyond the regulatory implications, successful KRYSTAL-12 data could pave the way for discussions about Krazati's use in earlier lines of therapy. While the current indication is for second-line treatment, demonstrating clear superiority in this setting could build a strong case for combination strategies or even monotherapy in first-line settings, significantly expanding its addressable patient population. The market is keenly watching for these results, as they will dictate Krazati's trajectory for years to come.
While KRYSTAL-12 is critical for Krazati's current indication, the true long-term growth potential lies in expanding its use into earlier treatment lines and other KRAS G12C-mutated solid tumors. This strategy is being pursued through several ongoing clinical trials, most notably KRYSTAL-7 and KRYSTAL-10, which aim to broaden Krazati's market footprint significantly. The oncology landscape is rapidly shifting towards first-line and combination therapies, and Krazati needs to adapt to stay competitive.
KRYSTAL-7 (NCT04613596) is a Phase 2/3 study investigating adagrasib in combination with pembrolizumab, a widely used immune checkpoint inhibitor, for first-line treatment of advanced/metastatic KRAS G12C-mutated NSCLC. Initial Phase 2 data, presented at ELCC 2025, showed promising efficacy and a manageable safety profile, particularly in patients with PD-L1 ≥50%. The ongoing Phase 3 portion of KRYSTAL-7 directly compares adagrasib plus pembrolizumab against pembrolizumab alone in this patient subset, with results expected to be a major catalyst. Success here would unlock a much larger patient population and establish Krazati as a front-line option.
Beyond NSCLC, Krazati is also being evaluated in other KRAS G12C-mutated cancers. The KRYSTAL-10 study (NCT04685135) is a Phase 3 trial combining adagrasib with cetuximab versus chemotherapy in patients with advanced colorectal cancer (CRC) with a KRAS G12C mutation. CRC represents another significant unmet need, with KRAS G12C mutations occurring in about 30% of cases. Positive data from KRYSTAL-10, with a trial completion date projected for July 2026, could provide Krazati with a crucial second indication, diversifying its revenue streams.
Furthermore, Mirati (now BMS) is actively exploring other combination therapies. Collaborations include combining adagrasib with Sanofi’s SHP2 inhibitor and with Kura Oncology’s farnesyl transferase inhibitor KO-2806. These partnerships aim to enhance treatment durability and overcome resistance mechanisms, reflecting a broader strategy to maximize Krazati's potential across various tumor types and treatment settings. The ability to combine effectively with other agents will be key to Krazati's long-term success in a crowded market.
Krazati operates in an increasingly crowded and competitive KRAS inhibitor landscape, with several established and emerging players vying for market share. Amgen's Lumakras (sotorasib) is Krazati's most direct competitor, having been the first-in-class KRAS G12C inhibitor to receive FDA approval in May 2021. While Krazati has shown a higher ORR in its registrational trial, Lumakras has the advantage of being first to market and has also demonstrated intracranial efficacy, making the head-to-head comparison in real-world settings crucial.
The competition extends beyond G12C-specific inhibitors. Revolution Medicines is a formidable challenger with its pan-RAS(ON) tri-complex inhibitor, Daraxonrasib (RMC-6236). This drug has already announced positive Phase 3 overall survival (OS) data in pancreatic ductal adenocarcinoma (PDAC), a notoriously difficult-to-treat cancer, and a Phase 3 win in NSCLC. Daraxonrasib's ability to target a broader range of RAS mutations, not just G12C, positions it as a potential game-changer, addressing a larger unmet need.
Other companies are also advancing next-generation KRAS inhibitors. Eli Lilly's Olomorasib is in Phase 3 for NSCLC, including combination studies with pembrolizumab in the first-line setting (SUNRAY-01). Merck's Calderasib (MK-1084) and Roche/Genentech's Divarasib are also in Phase 3, specifically targeting the adjuvant NSCLC setting, which represents a much larger addressable population than metastatic disease. These drugs could shift the standard of care towards earlier intervention, intensifying competition for Krazati.
The competitive landscape is further complicated by the emergence of novel modalities like PROTAC degraders (e.g., Arvinas's Setidegrasib in Phase 3 for PDAC) and molecular glues (e.g., Roche's Elironrasib). These approaches aim to overcome resistance mechanisms that often develop with covalent G12C inhibitors, posing a significant long-term threat. Additionally, the development of G12D-specific inhibitors, such as Incyte's INCB-161734 and Revolution Medicines' Zoldonrasib, targets the largest unmet need in PDAC and CRC, further fragmenting the KRAS market. Krazati's ability to differentiate itself through combination therapies, CNS activity, and potential expansion into new indications will be vital to maintaining its competitive edge.
Mirati Therapeutics' financial performance, particularly its trailing twelve months (TTM) metrics, offers a snapshot of the company's position prior to its full integration into Bristol Myers Squibb. With a market capitalization of $4.12 billion and an Enterprise Value (EV) of $3.93 billion, Mirati was a significant acquisition for BMS, reflecting the perceived value of Krazati and its pipeline. However, the TTM financials reveal a company in a high-growth, pre-profitability stage, typical of a biotech focused on R&D and initial commercialization.
The TTM revenue stands at a modest $0.22 per share, translating to a Price-to-Sales (P/S) ratio of an astonishing 331.11. This extremely high P/S ratio underscores that investors were valuing Mirati based on Krazati's future revenue potential, rather than its current sales. Similarly, the negative P/E ratio of -4.46 and negative EPS of -$13.18 reflect the substantial R&D and commercialization costs associated with bringing a drug like Krazati to market. The operating margin of -6108.0% and net margin of -5957.4% further illustrate the significant investments being made relative to current revenue.
Despite these negative profitability metrics, the company's balance sheet showed strength, with a Current Ratio of 6.96, indicating ample liquidity to cover short-term obligations. The Debt-to-Equity (D/E) ratio of 0.05 suggests a low reliance on debt financing. These figures were likely attractive to BMS, as they indicated a relatively healthy financial foundation for a biotech company, albeit one that was burning cash to fund its pipeline and initial Krazati launch.
Analyst consensus for Mirati, prior to the acquisition, was a "Hold" rating, with a median price target of $66.50 against a current price of $58.70. This suggests a moderate upside expectation, reflecting both the promise of Krazati and the inherent risks in drug development and commercialization. The forward revenue estimates for FY 2024 and FY 2025 are $0.2 billion and $0.3 billion, respectively, indicating an anticipated ramp-up in Krazati sales as it gains market traction and potentially expands indications. For BMS, Krazati represents a strategic asset to bolster its oncology franchise, with the financial burden of its development now absorbed by a larger entity.
For investors, Mirati Therapeutics, now integrated into Bristol Myers Squibb, represents a play on the future success of Krazati and BMS's broader oncology strategy. The upcoming data readouts are not just scientific milestones; they are critical commercial catalysts that will shape Krazati's market share and revenue contribution to BMS. Positive results from KRYSTAL-12, particularly on overall survival, could solidify Krazati's position in second-line NSCLC and provide a strong foundation for future growth.
The expansion into first-line NSCLC with KRYSTAL-7 and into colorectal cancer with KRYSTAL-10 are the next major growth engines. Success in these broader indications would significantly increase Krazati's peak sales potential, making it a more substantial asset within BMS's portfolio. However, investors must also weigh the intensifying competitive landscape, where next-generation KRAS inhibitors and novel modalities are rapidly emerging, threatening to disrupt the market.
The EMA's initial negative opinion highlights the global regulatory complexities and the need for robust, differentiated data. A successful re-examination in Europe would open up a significant market, while continued delays could limit Krazati's international reach. Ultimately, Krazati's journey is a microcosm of the high-stakes, high-reward world of oncology drug development, where clinical data, regulatory approvals, and competitive positioning dictate long-term value.
The next 12-24 months will be pivotal for Krazati, with key data readouts and regulatory decisions expected to clarify its commercial trajectory and competitive standing. Investors in BMS should closely monitor these developments as they will directly impact the return on the $4.8 billion acquisition and the future growth of its oncology franchise.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
